Stoke Therapeutics, Inc. (STOK)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 4 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Stoke Therapeutics’ second fiscal quarter of 2026 results missed expectations on earnings, with EPS of -$0.93 trailing the -$0.80 estimate (difference -$0.14), as reported August 3, 2026. Revenue fell 33% to about $9.3 million from $13.8 million a year ago, alongside a net loss of roughly $61.6 million versus -$23.5 million a year ago, and operating income came in at around -$65.4 million as the company continued advancing its RNA-based medicines pipeline, including programs built on its TANGO platform. On a per-share basis, EPS was down 132% year over year from -$0.40, consistent with the wider net loss over the period. For the next period, consensus calls for EPS of -$0.88 on revenue of $8.2 million.
Next report — what to expect
Stoke Therapeutics, Inc. (STOK) is set to report earnings on November 3, 2026. Wall Street expects EPS of -$0.88 on revenue of $8.2 million. As trailing context, revenue fell -32.5% year over year last quarter. STOK has beaten EPS in 5 of its 8 most recent quarters.
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. develops RNA-based medicines in biotechnology and trades on the NASDAQ under STOK. The company focuses on antisense oligonucleotide therapies built to raise protein expression through its TANGO platform, which engineers ASOs to enhance protein expression, and it recorded $184.4 million in revenue in FY2025.
Today's Snapshot
STOK closed 2.6% lower on heavier trading than usual. Stoke Therapeutics scheduled a call to discuss third-quarter business and financial updates. STOK reports earnings on 3 November.
Trading Volume
Above 10d avg 1.1M
1.6M
vs S&P 500 Today
Underperforming Market
-2.05%
Updated: October 23, 2026 at 20:17 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$25.09 - $30.02Sell
- RSI (14)45.75Neutral
- Stochastic %K (14, 3, 3)66.22Neutral
- MACD Level (12, 26)-0.68Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.